← Leaderboards
Ronald T Mitsuyasu
University Of California Los Angeles
$121,811,876
Attributed
$121,811,876
Total exposure
43
Grants
30
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $24.2M · FY2005–19$25M$18.8M$12.5M$6.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$176,489,361 · 44
By mechanism
UM1$99,538,898 · 1
U01$71,103,315 · 10
M01$2,884,526 · 30
P30$1,869,849 · 1
R25$772,964 · 1
R21$319,809 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelResourcesAcquired Immunodeficiency SyndromeClinical ResearchAreaClinical TrialsGrantMalignant NeoplasmsLaboratoriesEnrollmentTumorHuman PapillomavirusProtocols DocumentationHuman SubjectInternationalSiteCommunitiesMissionPharmaceutical PreparationsSamplingLymphomaLeadershipPathologyInstitution
Grant awards (109)
AIDS Malignancy Consortium (AMC)$17,451,533
UM1 · FY2019 · CA · contact PI
AIDS Malignancy Consortium (AMC)$23,766,226
UM1 · FY2018 · CA · contact PI
AIDS Malignancy Consortium (AMC)$199,678
UM1 · FY2018 · CA · contact PI
Clinical Research Facilitation Core$168,356
P30 · FY2018 · AI · contact PI
AIDS Malignancy Consortium (AMC)$99,713
UM1 · FY2018 · CA · contact PI
AIDS Malignancy Consortium (AMC)$23,267,256
UM1 · FY2017 · CA · contact PI
Clinical Research Facilitation Core$337,589
P30 · FY2017 · AI · contact PI
AIDS Malignancy Consortium (AMC)$21,619,997
UM1 · FY2016 · CA · contact PI
Clinical Research Facilitation Core$337,876
P30 · FY2016 · AI · contact PI
AIDS Malignancy Consortium (AMC)$13,134,495
UM1 · FY2015 · CA · contact PI
Clinical Research Facilitation Core$338,301
P30 · FY2015 · AI · contact PI
AIDS Malignancy Clinical Trials Consortium (AMC)$6,300,000
U01 · FY2014 · CA · contact PI
AIDS Malignancy Clinical Trials Consortium (AMC)$1,900,000
U01 · FY2014 · CA · contact PI
Clinical Research Facilitation Core$348,728
P30 · FY2014 · AI · contact PI
AMC Group Chairman, University of California, LA$236,084
U01 · FY2014 · CA · contact PI
UCLA-USC Combined Los Angeles Core Site$166,391
U01 · FY2014 · CA · contact PI
Network Core Research Lab$166,390
U01 · FY2014 · CA · contact PI
Studies on the Prevalence, Risk Factors and Outcomes of Cancers in HIV in India$154,758
R21 · FY2014 · CA · contact PI
AIDS Malignancy Clinical Trials Consortium (AMC)$6,477,537
U01 · FY2013 · CA · contact PI
AIDS Malignancy Clinical Trials Consortium (AMC)$5,600,000
U01 · FY2013 · CA · contact PI
AMC Group Chairman, University of California, LA$634,440
U01 · FY2013 · CA · contact PI
UCLA-USC Combined Los Angeles Core Site$584,310
U01 · FY2013 · CA · contact PI
Network Core Research Lab$584,308
U01 · FY2013 · CA · contact PI
Clinical Research Facilitation Core$338,999
P30 · FY2013 · AI · contact PI
South American Prevention of HIV Research Training Program (SAPHIR)$253,344
R25 · FY2013 · MH · contact PI
Studies on the Prevalence, Risk Factors and Outcomes of Cancers in HIV in India$165,051
R21 · FY2013 · CA · contact PI
AIDS Malignancy Clinical Trials Consortium (AMC)$6,010,333
U01 · FY2012 · CA · contact PI
AMC Group Chairman, University of California, LA$594,873
U01 · FY2012 · CA · contact PI
UCLA-USC Combined Los Angeles Core Site$541,546
U01 · FY2012 · CA · contact PI
Network Core Research Lab$541,545
U01 · FY2012 · CA · contact PI
AIDS Malignancy Clinical Trials Consortium (AMC)$450,000
U01 · FY2012 · CA · contact PI
South American Prevention of HIV Research Training Program (SAPHIR)$267,615
R25 · FY2012 · MH · contact PI
AMC Group Chairman, University of California, LA$40,910
U01 · FY2012 · CA · contact PI
UCLA-USC Combined Los Angeles Core Site$40,909
U01 · FY2012 · CA · contact PI
Network Core Research Lab$40,909
U01 · FY2012 · CA · contact PI
AIDS Malignancy Clinical Trials Consortium (AMC)$5,189,968
U01 · FY2011 · CA · contact PI
AMC Group Chairman, University of California, LA$609,928
U01 · FY2011 · CA · contact PI
Network Core Research Lab$538,004
U01 · FY2011 · CA · contact PI
UCLA-USC Combined Los Angeles Core Site$538,004
U01 · FY2011 · CA · contact PI
AIDS Malignancy Clinical Trials Consortium (AMC)$450,000
U01 · FY2011 · CA · contact PI
South American Prevention of HIV Research Training Program (SAPHIR)$252,005
R25 · FY2011 · MH · contact PI
AIDS Malignancy Clinical Trials Consortium (AMC)$200,000
U01 · FY2011 · CA · contact PI
AIDS Malignancy Clinical Trials Consortium (AMC)$150,000
U01 · FY2011 · CA · contact PI
AIDS Malignancy Clinical Trials Consortium (AMC)$4,660,100
U01 · FY2010 · CA · contact PI
AMC Group Chairman, University of California, LA$480,760
U01 · FY2010 · CA · contact PI
Network Core Research Lab$417,934
U01 · FY2010 · CA · contact PI
UCLA-USC Combined Los Angeles Core Site$417,934
U01 · FY2010 · CA · contact PI
A SINGLE ARM, OPEN-LABEL PILOT TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A QUADR$94,148
M01 · FY2010 · RR · contact PI
A PHASE II TRIAL OF COMBINED MODALITY THERAPY PLUS CETUXIMAB IN HIV-ASSOCIATED A$10,459
M01 · FY2010 · RR · contact PI
A PHASE II TRIAL OF DOXIL, RITUXIMAB, CYCLOPHOSPHAMIDE, VINCRISTINE, AND PREDNIS$4,483
M01 · FY2010 · RR · contact PI
A PROSPECTIVE PHASE II STUDY OF A HIGH DOSE, SHORT COURSE REGIMEN (R-CODOX-M/IVA$1,493
M01 · FY2010 · RR · contact PI
PHASE IIA TRIAL OF 1% TOPICAL CIDOFOVIR FOR TREATMENT OF HIGH-GRADE PERIANAL SQU$1,493
M01 · FY2010 · RR · contact PI
AIDS Malignancy Clinical Trials Consortium$3,605,692
U01 · FY2009 · CA · contact PI
A SINGLE ARM, OPEN-LABEL PILOT TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A QUADR$93,970
M01 · FY2009 · RR · contact PI
DOUBLE-BLIND PHASE II STUDY OF MULTIPLE DOSES OF PALIFERMIN (RHUKGF) FOR AIDS$49,921
M01 · FY2009 · RR · contact PI
AIDS Malignancy Clinical Trials Consortium$25,000
U01 · FY2009 · CA · contact PI
A PHASE II TRIAL OF DOXIL, RITUXIMAB, CYCLOPHOSPHAMIDE,$13,215
M01 · FY2009 · RR · contact PI
SHORT COURSE REGIMEN (R-CODOX-M/IVAC) I$7,343
M01 · FY2009 · RR · contact PI
PHASE IIA TRIAL OF 1% TOPICAL CIDOFOVIR FOR TREATMENT OF HIGH-GRADE PERIANAL SQU$1,467
M01 · FY2009 · RR · contact PI
AIDS Malignancy Clinical Trials Consortium$3,732,363
U01 · FY2008 · CA · contact PI
AIDS Malignancy Clinical Trials Consortium$250,067
U01 · FY2008 · CA · contact PI
AIDS Malignancy Clinical Trials Consortium$249,599
U01 · FY2008 · CA · contact PI
AIDS Malignancy Clinical Trials Consortium$25,000
U01 · FY2008 · CA · contact PI
A PHASE II TRIAL OF IMATINIB MESYLATE (GLEEVEC) IN PATIENTS WITH HIV RELATED$19,327
M01 · FY2008 · RR · contact PI
AMC 036: A PHASE II TRIAL OF TOPICAL HALOFUGINONE IN PATIENTS WITH HIV RELAT$5,271
M01 · FY2008 · RR · contact PI
A PHASE II DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE$3,515
M01 · FY2008 · RR · contact PI
AIDS Malignancy Clinical Trials Consortium$5,496,387
U01 · FY2007 · CA · contact PI
A PHASE II DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE$14,386
M01 · FY2007 · RR · contact PI
A PHASE II TRIAL OF IMATINIB MESYLATE (GLEEVEC) IN PATIENTS WITH HIV RELATED$8,855
M01 · FY2007 · RR · contact PI
AMC 036: A PHASE II TRIAL OF TOPICAL HALOFUGINONE IN PATIENTS WITH HIV RELAT$2,214
M01 · FY2007 · RR · contact PI
AIDS Malignancy Clinical Trials Consortium$3,805,478
U01 · FY2006 · CA · contact PI
Discretionary Funding$400,000
U01 · FY2006 · CA · contact PI
Recruitment and Retention$400,000
U01 · FY2006 · CA · contact PI
Funding Plan Additions$300,000
U01 · FY2006 · CA · contact PI
Group Chair Administrative Office & Overview of Entire Application$209,801
U01 · FY2006 · CA · contact PI
AIDS Malignancy Clinical Trials Consortium$99,961
U01 · FY2006 · CA · contact PI
A PHASE II DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE$10,418
M01 · FY2006 · RR · contact PI
IMPROVING IMMUNE RECONSTRUCTION WITH GROWTH HORMONE IN HIV-INFECTED SUBJECTS$3,126
M01 · FY2006 · RR · contact PI
AMC 036: A PHASE II TRIAL OF TOPICAL HALOFUGINONE IN PATIENTS WITH HIV RELAT$1,041
M01 · FY2006 · RR · contact PI
AIDS-ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUM$595,687
U01 · FY2005 · CA
AIDS-ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUM$143,589
U01 · FY2005 · CA
IMPROVING IMMUNE RECONSTRUCTION WITH GROWTH HORMONE IN HIV-INFECTED SUBJECTS$21,725
M01 · FY2005 · RR
A RANDOMIZED PHASE I/II PILOT STUDY OF INTERMITTENT WITHDRAWAL OF ANTIRETROVI$3,292
M01 · FY2005 · RR
RANDOMIZED TRIAL OF STANDARD CHEMOTHERAPY WITH OR WITHOUT THE ADDITION OF RITUX)$1,317
M01 · FY2005 · RR
AIDS-ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUM$218,459
U01 · FY2004 · CA
IMPROVING IMMUNE RECONSTRUCTION WITH GROWTH HORMONE IN HIV-INFECTED SUBJECTS...$16,676
M01 · FY2004 · RR
EXPLORATORY, OPEN-LABEL, RANDOMIZED TRIAL TO EVALUATE$1,853
M01 · FY2004 · RR
Rituxan for Treatment of HIV-Associated Non-Hodgkin's Ly$617
M01 · FY2004 · RR
AIDS CLINICAL TRIALS UNIT$1,717,114
U01 · FY2003 · AI
AIDS-ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUM$252,522
U01 · FY2003 · CA
AIDS CLINICAL TRIALS UNIT$1,760,834
U01 · FY2002 · AI
AIDS CLINICAL TRIALS UNIT$1,640,820
U01 · FY2001 · AI
PHASE II STUDY OF THE ACTIVITY AND SAFETY OF AUTOLOGUS CD4-ZETA GENE-MODIFIED$207,266
M01 · FY2001 · RR
PHASE I TRIAL OF CD34+ STEM CELLS TRANSDUCED WITH AN HIV RIBOZYME$207,266
M01 · FY2001 · RR
AUTOLOGOUS CD4 ZETA GENE MODIFIED T CELLS IN HIV INFECTED PATIENTS$207,266
M01 · FY2001 · RR
AUTOLOGOUS CD4 ZETA GENE MODIFIED T CELLS IN HIV INFECTED PATIENTS$207,266
M01 · FY2001 · RR
PHASE II STUDY OF AUTOLOGOUS CD4 ZETA GENE MODIFIED T CELLS IN HIV$207,266
M01 · FY2001 · RR
PHASE II STUDY OF INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN-2 BY INTRAVENOUSLY$207,266
M01 · FY2001 · RR
PHASE II STUDY OF INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN-2 BY INTRAVENOUSLY$207,266
M01 · FY2001 · RR
COMPARISON STUDY OF LIPOSOMAL DOXORUBICIN TO TREAT AIDS KAPOSI'S SARCOMA$207,266
M01 · FY2001 · RR
PHASE I TRIAL OF CD34+ STEM CELLS TRANSDUCED WITH AN HIV RIBOZYME$207,266
M01 · FY2001 · RR
PHASE I TRIAL OF ANTITUMOR ACTIVITY OF INF ALPHA$0
M01 · FY2001 · RR
AIDS CLINICAL TRIALS UNIT$1,611,825
U01 · FY2000 · AI
PHASE II STUDY OF THE ACTIVITY AND SAFETY OF AUTOLOGUS CD4-ZETA GENE-MODIFIED$207,266
M01 · FY2000 · RR
PHASE II STUDY OF AUTOLOGOUS CD4 ZETA GENE MODIFIED T CELLS IN HIV$207,266
M01 · FY2000 · RR
COMPARISON STUDY OF LIPOSOMAL DOXORUBICIN TO TREAT AIDS KAPOSI'S SARCOMA$207,266
M01 · FY2000 · RR
PHASE II STUDY OF THE ACTIVITY AND SAFETY OF AUTOLOGUS CD4-ZETA GENE-MODIFIED$1,903
M01 · FY2000 · RR
PHASE II STUDY OF AUTOLOGOUS CD4 ZETA GENE MODIFIED T CELLS IN HIV$1,903
M01 · FY2000 · RR
COMPARISON STUDY OF LIPOSOMAL DOXORUBICIN TO TREAT AIDS KAPOSI'S SARCOMA$1,903
M01 · FY2000 · RR